Firms unite to develop antibiotics against drug-resistant bacteria

09/12/2013 | Pharmaceutical Business Review Online

Swiss firm Debiopharm Group and TCG Lifesciences, a contract research services company, agreed to jointly develop antibiotics against drug-resistant bacteria. Debiopharm will fund the collaboration and share its drug development expertise. TCG's "extensive experience in medicinal chemistry and infectious diseases is a major asset for the development of Debio 1348," Debiopharm President Rolland-Yves Mauvernay said.

View Full Article in:

Pharmaceutical Business Review Online

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Assistant General Counsel, Regulatory
Cardinal Health
Waukegan, IL
Chief Executive Officer
UCare Minnesota
Minneapolis, MN